Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

DYNA001

Sigma-Aldrich

DyNAbind® DNA-Encoded Fragment Library

Synonym(s):

DNA encoded library, DNA library

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41105521
NACRES:
NA.22

form

pellets

storage temp.

−20°C

Application

DNA-encoded library (DEL) technology is a drug discovery tool containing small DNA-barcoded compounds (Satz 2018). The DyNAbind fragment DEL contains small molecular weight compounds. The high ligand efficiency of fragment molecules is harnessed to effectively probe a target′s binding site and increase the likelihood of discovering binders (Murray and Rees 2009, Murray et al. 2012). Moreover, this library uses DyNAbind′s proprietary Dynamic Library technology to drive binder optimization and reveal not only individual fragments, but also joined fragment pairs for over 370,000 highly diverse structures (Reddavide et al. 2015, Reddavide et al. 2019). DyNAbind′s proprietary Dynamic Library technology reshuffles fragment pairs to automatically optimize the affinity of binders and increase the chances of finding good hits. After a pooled screening approach, bound fragments can be determined using next-generation sequencing of the barcodes. Analysis of the sequencing data is provided at no additional cost through a portal on our website which will generate a list of the fragments that bind the target. These fragments can be used as structural starting points to develop larger, more drug-like compounds.

Analysis Portal

More information about DyNAbind

Features and Benefits

Product Features and Benefits:

  • Off-the-shelf, affordable access to DEL technology
  • Dynamic fragment library provides a revolutionary approach to DELs offering unprecedented library and data quality
  • High level quality control with every single member individually purified and validated to maximize data reliability and chances for finding good hits
  • Rule of Three used in library design ensures compounds are in favorable fragment space with good ligand efficiency and plenty of room for optimization (Congreve et al. 2003, Jhoti et al. 2013)
  • Ability to perform and validate initial DEL screening internally before engaging service provider
  • A library with maximized diversity, ready to deploy against nearly any druggable target

Product Overview:

  • Dynamic fragment-based DEL as alternative or complement to existing screening technologies
  • Consumable, off-the-shelf product for immediate use
  • 5 vials, each containing a single-use library for one experimental condition
  • Detailed protocol accessible to most drug discovery labs
  • A dedicated analysis portal and protocol to identify hits

Legal Information

Product of DyNAbind GmbH

The use of this DyNAbind Product (the “Product”) is covered by European Patents EP 3 094 745 B1 and EP 3 169 832 B1 and corresponding applications pending in the US, Canada, and Japan. Purchaser is granted the right to use the Product for its internal research use only. This limited use label license does not grant the purchaser any right to use resulting fragments or products in commercial products or services. For information on commercial rights, please contact the outlicensing department at licensing@dynabind.com.
DyNAbind is a registered trademark of DyNAbind GmbH

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCJ7689

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The 'rule of three' for fragment-based drug discovery: where are we now?
Harren Jhoti et al.
Nature reviews. Drug discovery, 12(8), 644-645 (2013-07-13)
Christopher W Murray et al.
Trends in pharmacological sciences, 33(5), 224-232 (2012-03-31)
Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for the generation of chemical leads for drug targets. In FBDD, specialised detection methods are used to identify small chemical compounds
Francesco V Reddavide et al.
Angewandte Chemie (International ed. in English), 54(27), 7924-7928 (2015-05-28)
Dynamic combinatorial chemistry (DCC) explores the thermodynamic equilibrium of reversible reactions. Its application in the discovery of protein binders is largely limited by difficulties in the analysis of complex reaction mixtures. DNA-encoded chemical library (DECL) technology allows the selection of
Alexander L Satz
ACS medicinal chemistry letters, 9(5), 408-410 (2018-05-26)
Use of DNA-encoded libraries (DELs) in the pharmaceutical industry has rapidly increased. We discuss what to expect when you run a DEL screen and contemplate guidelines for library design. Additionally, we consider some visionary work and extrapolate to the future.
A 'rule of three' for fragment-based lead discovery?
Miles Congreve et al.
Drug discovery today, 8(19), 876-877 (2003-10-14)
View All Related Papers

Articles

Fragment-Based DNA-Encoded Library for Drug Discovery

Unprecedented access to large library drug discovery, Dynamic Library technology offers more reliable results than classical DEL approaches, library members selected for MedChem relevance, high chemical diversity, suitable for a number of targets

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service